Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail of drugs takes on Hard-to-Treat colon cancer

NCT ID NCT04660812

Disease control Sponsor: Arcus Biosciences, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested combinations of a new drug called etrumadenant (AB928) with other treatments in 227 people whose colorectal cancer had spread. The goal was to see if these combinations could shrink tumors or slow the cancer's growth. Participants received different drug mixes, including chemotherapy and immunotherapy, to find safer and more effective options.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Etrumadenant (AB928) combined with other drugs (AB680, zimberelimab, bevacizumab, chemotherapy)
What this could lead to
If successful, this could point toward a new treatment option for people with metastatic colorectal cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (phase 1b/2) with a small number of participants, so results may not apply to all patients. The drug combinations may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

227 people

The number who actually took part.

Started

May 2021

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female participants ≥ 18 years of age * Histologically confirmed metastatic colorectal adenocarcinoma * Must have at least 1 measurable lesion per RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy at least 3 months * Adequate hematologic and end-organ function * Negative HIV, Hep B and Hep C antibody testing * Agreement to remain abstinent or use contraceptive measures with female partners of reproductive potential, and agreement to refrain from donating sperm, for 30 days after the last dose of etrumadenant, 90 days after the last dose of zim, 180 days after mFOLFOX-6 and 180 days after bev, whichever is longer. * Inclusion Criteria for Cohort A: * Disease progression following not more than one prior line of treatment for mCRC that consisted of oxaliplatin or irinotecan containing chemotherapy in combination with a biologic agent * Inclusion Criteria for Cohort B: * Disease progression during or following not more than two separate lines of treatment for mCRC that consisted of oxaliplatin, and irinotecan containing chemotherapy in combination with a biologic agent Exclusion Criteria: * Previous anticancer treatment within 4 weeks prior to initiation of study treatment * Prior allogeneic stem cell or solid organ transplant * Treatment with systemic immunostimulatory agents within 4 weeks prior to initiation of study treatment * Use of any live vaccines against infectious diseases within 28 days of first dose. * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases * Current treatment with anti-viral therapy for HBV * Structurally unstable bone lesions suggesting impending fracture * History or leptomeningeal disease * History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan * History of malignancy other than colorectal cancer within 2 years prior to screening, except for malignancies such as non-melanoma skin carcinoma or ductal carcinoma in situ * Active tuberculosis * Treatment with therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to initiating study treatment * Severe infection within 4 weeks (28 days) prior to initiation of study treatment * Significant cardiovascular disease, unstable or new onset of angina within 3 months prior to initiation of treatment, or myocardial infarction within 6 months prior to study treatment or unstable arrhythmia * Major surgical procedures, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for major surgical procedure during the study * Known allergy or hypersensitivity to any of the study drugs or their excipients * Inability to swallow medications * Malabsorption condition that would alter the absorption of orally administered medications * Evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation) * Prior treatment with an agent targeting the adenosine pathway * Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain Barré syndrome, or multiple sclerosis * Exclusion Criteria for Cohorts A and B: * Prior treatment with immune checkpoint blockade therapies including anti-cytotoxic T lymphocyte-associated protein-4, anti PD-1, and anti-PD-L1 therapeutic antibodies * Mutation in the BRAF oncogene. Patients with unknown BRAF status will be required to undergo testing at a local laboratory and provide results at screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic colorectal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic colorectal cancer

Contacts and locations

Locations

  • Aberdeen Royal Infirmary

    Aberdeen, Scotland, AB25 2ZN, United Kingdom

  • American Oncology Partners of Maryland PA

    Bethesda, Maryland, 20817, United States

  • Arizona Clinical Research Center Inc

    Tucson, Arizona, 85715, United States

  • Asan Medical Center | University of Ulsan College of Medicine

    Seoul, 5538, South Korea

  • Azienda Ospedaliera Niguarda Ca' Granda

    Milan, 20141, Italy

  • Azienda Ospedaliero Universitaria Careggi-S.O.D. Patologia Medica

    Florence, 50134, Italy

  • Belfast City Hospital

    Belfast, Northern Ireland, BT9 7AB, United Kingdom

  • CHU la Miletrie

    Poitiers, 86000, France

  • Centre Georges Francois Leclerc

    Dijon, 21000, France

  • Chonnam National University Hwasun Hospital

    Hwasun, 58128, South Korea

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • Clinica Universidad Navarra-Sede Madrid

    Pamplona, 31008, Spain

  • Complejo Hospitalario de Orense

    Ourense, 32005, Spain

  • Comprehensive Cancer Centers Of Nevada

    Las Vegas, Nevada, 89169, United States

  • Corporacio Sanitaria Parc Tauli

    Sabadell, 8208, Spain

  • Groupe Hospitalier Pitie-Salpetriere-Centre De Recherche et de Medecine de l'Obesite

    Paris, 75651, France

  • Hopital Hotel Dieu

    Nantes, 44093, France

  • Hopital Saint Antoine

    Paris, 75012, France

  • Hospital General Universitario Gregorio Maranon

    Madrid, 28046, Spain

  • Hospital Universitario La Paz

    Madrid, 28007, Spain

  • IRCCS - Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis

    Castellana Grotte, 70013, Italy

  • Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest

    Bordeaux, 33076, France

  • Instituto Europeo di Oncologia

    Milan, 20162, Italy

  • Istituto Clinico Humanitas IRCCS

    Rozzano, 20089, Italy

  • Korea University Anam Hospital

    Seoul, 8241, South Korea

  • Kyungpook National University Chilgok Hospital

    Seoul, South Korea

  • NYU Langone Medical Center - NYU Medical Oncology Associates

    New York, New York, 10016, United States

  • New York-Presbyterian Hospital-Columbia University Medical Center

    New York, New York, 10032, United States

  • Ochsner Medical Center (OMC)

    New Orleans, Louisiana, 70121, United States

  • Prisma Health-Upstate

    Greenville, South Carolina, 29605, United States

  • Samsung Medical Center

    Seoul, 6351, South Korea

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37232, United States

  • Seoul National University Bundang Hospital

    Seoul, 13620, South Korea

  • Seoul National University Hospital (SNUH)

    Seoul, 3080, South Korea

  • Severance Hospital | Yonsei University Health System

    Seoul, 3722, South Korea

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia, 20016-2633, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • UCLA Hematology Oncology

    Santa Monica, California, 90404, United States

  • Universita di Siena - Azienda Ospedaliera Universitaria Senese-Policlincio Santa Maria Alle Scotte

    Siena, 53100, Italy

  • University of Wisconsin School of Medicine

    Madison, Wisconsin, 53792, United States

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee, 37203, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Winship Cancer Institute at Emory University

    Atlanta, Georgia, 30322, United States

  • Yale Cancer Center

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.